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Purpose: The main objective of this study was to measure serum complement C3 and C4 
concentrations in patients of lupus nephritis to see if these simple measurements would give useful 
information to the clinician managing such patients.. 
Method: A total of 52 samples were obtained from SLE patients, 17 suffering from lupus nephritis. All 
patients met the revised 1997 American College of Rheumatology criteria for SLE. Serum C3 and C4 
concentrations were measured with single gel radioimmunodiffusion technique. 
Results: In lupus nephritis, C3 and C4 are generally correlated.  Both C3 and C4 levels were decreased 
but C4 concentrations were more often and more profoundly depressed than C3 concentration. 
Conclusion: All patients of lupus nephritis with low C3 or C4 concentrations should have serial 
measurements performed and selected patients will need a full complement profile, including 
measurement of alternate pathway components and total hemolytic pathway. 
 
 
Key Words: Systemic lupus erythematosus, Auto antibodies, Lupus nephritis, C3 and C4 
 
 





*Corresponding author: Department of Microbiology and Molecular Genetics, Quaid-e-Azam Campus, University of 
the Punjab, Lahore-Pakistan. 
 
Hussain et al 
Trop J Pharm Res December 2008; 7 (4) 1118 
INTRODUCTION 
Systemic Lupus Erythematosus (SLE) is a 
relatively common autoimmune disorder that 
results in the production of an array of 
autoantibodies
1,2
. The complement system 
consists of 11 components which together 
form some 10% of circulating plasma protein. 
The association between the complement 
system and SLE is contradictory
3,4
. The 
complement system has long been known to 
be activated in exacerbations of SLE, 
particularly reflecting nephritic activity
5,6,7
. It 
has been debated whether this complement 
activation is important in the pathogenesis of 
SLE or whether it is an innocent 
epiphenomenon. Complement is a mediator of 
inflammation, complement deficiency 
predisposes to the development of SLE. 
Inherited complement C4 deficiency, whether 
partial or complete, confer a high risk to 
developing SLE, whereas C3 deficiency is 




The association between complement 
deficiencies and SLE supports an important 
role of complement in preventing immune 
complex mediated tissue damage
10
. However, 
increased activation of complement without 
deficiencies may also contribute to the tissue 
damage in SLE, since it was recently shown in 
an experimental mouse SLE model that 
specific inhibition of complement abolished 




The role of complement in lupus was 
examined in mouse models. The first model is 
based on the hypothesis that complement 
plays a substantial role in the clearance of 
immune complexes and/or apoptotic debris, 
which is thought to be impaired in lupus.  
Apoptotic bodies are a potential major source 
of lupus self antigens, and failure to remove 
them could lead to inappropriate production of 
pathogenic autoantibodies. Support for a role 
for early complement in clearance of apoptotic 
debris comes from the finding that mice 
deficient in C4 have defects in the clearance 
of injected apoptotic thymocytes. Moreover 
mice deficient in C4 spontaneously develop 
autoantibodies against nuclear antigens. The 
presence of increased apoptotic bodies in the 





A second nonexclusive model proposes that 
the innate immune system, including 
complement, is protective against lupus by 
enhancing negative selection of self-reactive 
B cells. According to this hypothesis, innate 
proteins enhance the localization of lupus 
antigens such as dsDNA and nuclear proteins 
within the primary lymphoid compartment. 
Efficient presentation of self-antigens results 
in elimination or editing of potential self-
reactive B-cells. Thus deficiency in innate 
proteins such as serum amyloid protein, 
DNAse I, natural IgM, C1q or C4 could lead to 
an escape from negative selection of self-
reactive B cells and their potential activation in 
the periphery in the presence of cognate T cell 
help and lupus antigen.
15,16
 
We have measured C3 and C4 concentrations 
using commercially available immunodiffusion 
plates to see if these readily available, simple 
measurements would give useful information 
to the clinician managing patients with lupus 
nephritis. 
 
MATERIALS AND METHODS  
Altogether fifty-two blood samples were 
obtained from SLE patients during the period 
February 2007 - February 2008. All the 
patients included in this prospective study 
fulfilled 4 or more of the American 
Rheumatism Association Classification 
Criteria for SLE. Of the 52 SLE patients, 17 
were cases of lupus nephritis. Blood samples 
were obtained in an empty vacutainer tubes 
for the preparation of serum. Serum was 
obtained by allowing the blood to clot at room 
temperature for two hours and the tube was 
then centrifuged. Serum was removed, 
aliquoted and stored at -70
0
C. The C3 and C4 
concentrations were usually obtained within 
one week of receipt. Consent was taken from 
all patients before blood sampling. This 
research was approved by the ethical 
committee of Punjab University, Lahore-
Pakistan. 
C3 and C4 were measured by using 
immunodiffusion plates (FAR Ven Fermi, 12-
Italy) as described by the manufacturer. 
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These tests define serum proteins by single 
radial immunodiffusion plate. An amount of 
serum was placed in the agarose well, 
containing a mono-specific antibody. The 
serum spreads in the agarose and the 
contained antigen forms an immune complex 
with the antibody. A precipitation ring whose 
dimension is proportional to the concentration 
of protein in the serum was formed. Sample 
precipitation diameter was measured and the 
reference value table was used to read the 
concentration of the protein
17
. Other 
immunological techniques for the confirmation 
of diagnosis of SLE (ANA, dsDNA, Sm, SSA, 
SSB, anti-Histone, RibP) were preformed by 




A total of 52 patients with SLE were enrolled 
in our study. Of the 52, 17 were cases of 
lupus nephritis. Patients were diagnosed as 
having SLE based on the 1982 revised criteria 
proposed by the American College of 
Rheumatology
18
. In our lupus nephritis 
patients, fourteen (82.35%) were females and 
three (17.64%) were males.  
Mean age at entry to the study was 28.1yrs 
(range 11-60). C3 and C4 were measured by 
using immunodiffusion plates. Serum C3 and 
C4 concentrations (C3 = 50-120mg/dl, C4= 
20-50mg/dl) were normal in four (23.5%) 
lupus nephritis patients.  Low C3 and normal 
C4 concentrations were found in only two 
patients (11.7%). Normal C3 and low C4 
concentrations (35.29%) were commonest in 
lupus nephritis group as shown in Fig 1. Five 
patients (29.4%) with lupus nephritis showed 
low C3 in the presence of low C4 
concentration. These findings are summarized 
in Fig 2.  
The results of the laboratory investigations are 
shown in Table 1. Renal disorder was 
characterized by proteinuria and red cell cast. 
Hematological disorders include normocytic 
normochromic anaemia (64.7%), elevated 
ESR (100%), thrombocytopenia (23.52%) 
while total Leukocyte count, differential 
leukocyte count were normal. Immunological 
parameters like ANA, dsDNA were performed 
by an indirect ELISA technique; positive ANA 
was observed in 88.23% while positive dsDNA 
was found in 82.35% of the lupus nephritis 
patients. High urea (70.58%) and high 
creatinine (88.23%) levels were the best 
indicators suggestive of lupus nephritis. Lupus 
nephritis patients were treated according to 
the disease activity. 
 
DISCUSSION 
Of the components of the “classical pathway” 
of complement activation, the easiest to 
measure is C4. Its measurement together with 
that of C3 should enhance the understanding 
of the mechanisms involved and aid the 
clinical definition of lupus nephritis. C3 is a 
good screening test for lupus patients with 
renal disease.  
Lupus nephritis is generally considered to be 
the best established human model of chronic 
soluble complex renal disease
19
. It is not 
surprising; therefore to find that C4 was 
depleted more than C3, since soluble 
complexes activate the classical pathway.  
C4 concentration was low in most of the lupus 
nephritis patients, but this was not associated 
with increased complement activation. Low C4 
levels may falsely be regarded as classical 
pathway activation. Several other factors may 
explain low C4 values in SLE. Partial defects 
or homozygous defects in either C4A or/and 
C4B will result in reduced levels of total C4. 
Reduced synthesis or increased catabolism of 
C4 without corresponding complement 
activation may also explain low C4 values.
 
In 2002, Eniav found that the development of 
severe SLE in the absence of both classical 
and alternative complement pathways 
suggests that it is the absence of C4, and not 
the presence of C3 that is critical in SLE 
pathogenesis
20
. Thus, this study supports our 
research in the reference that complement C4 
provides an important protective role against 
the development of SLE. Cameron studied 55 
samples of Lupus nephritis and he also found 
that low plasma C4 concentrations were 
commonest in lupus nephritis group, but a C3 
concentration of below 20% of reference 





1999, Mollnes found that the complement 
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tests are of limited importance in routine 
examination of SLE without nephritis, and 
terminal complement complex was suggested 
to be one of the most sensitive markers for 
disease activity
22
. This study tells us the 
importance of measuring C3 and C4 
concentrations in lupus nephritis patients 
because C3 and C4 reflect the level of the 








Fig 2: Levels of C3 and C4 in lupus patients. C3: •  C4: 
 
 
Table 1: Hematological, biochemical and immunological parameters in lupus nephritis patients 
 






High Urea  70.58% 
High Creatinine 88.23% 
Immunological 
Positive ANA 88.23% 
Positive dsDNA 82.35% 
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From this data, it is suggested that all patients 
with lupus nephritis should have the C3 
concentration of their plasma or serum 
estimated. All those with a low C3 or 
suspected lupus nephritis should have C4 
estimation in addition. All patients with low C3 
or C4 concentrations should have serial 
measurements performed to see if the 
alterations reverse within a few weeks or 
persist. 
Most patients with a persistently low C3 or C4 
concentration will need a renal biopsy at some 
point and should of course be measured for 
lupus nephritis. Selected patients will need a 
full complement profile, including 
measurement of alternate pathway 
components and total hemolytic pathway. 
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